Shares of Nyxoah jumped 11.3% to $1.68 after the Belgian medtech firm reported that its U.S. pivotal trial for a hard-to-treat subset of sleep apnea patients hit every key benchmark. The results are the strongest clinical card the company has played yet — but with trailing revenue of just $17.9 million and a market cap around $170 million, the distance between trial success and meaningful sales growth remains vast.
The Numbers Beat Nyxoah's Own Prior Trial — And the Competition Can't Legally Treat These Patients
The study reported a 77.2% responder rate on its primary breathing-disruption measure (p<0.001) and zero device-related serious adverse events through 12 months. That handily tops Nyxoah's earlier U.S. trial in standard sleep apnea patients, which posted a 63.5% responder rate. Critically, patients with this specific airway condition — called complete concentric collapse — are currently ruled out for the rival Inspire device, the dominant player with over 100,000 implants worldwide. If the FDA grants an expanded label, Nyxoah would own the only nerve-stimulation option for this group in the U.S.
An FDA Filing Is Coming, But the Clock Still Ticks
Nyxoah is preparing a supplemental FDA submission to expand its device's approved use under its Breakthrough Device Designation. That designation typically speeds review, but approval is not guaranteed. Full data will be presented at a surgical sleep conference in Los Angeles in October 2026 — a key moment for physician buy-in.
Revenue Is Growing Fast From a Tiny Base — Cash Burn Looms Large
Q1 2026 revenue hit €6.37 million, up from €1.06 million a year earlier , and management has backed full-year 2026 revenue guidance of €36–40 million. Yet trailing losses stand near $96 million against just $97.8 million in cash , meaning the company likely needs the CCC expansion to work — and soon — to avoid another capital raise. Nyxoah already closed $110 million in financing this year to fund its U.S. launch.
Analyst Consensus Says Buy, but Price Targets Keep Falling
Five analysts rate the stock a "Buy" with an average price target of $8.90 — more than five times the current price. Yet Piper Sandler recently cut its target to $7 from $9 , signaling that even bulls are tempering expectations as the commercial ramp competes with cash drain. The trial win is real. Whether it arrives in time is the open question.